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Irreversible inhibitors that modify cysteine or lysine
residues within a protein kinase ATP binding site
offer, through their distinctive mode of action, an
alternative to ATP-competitive agents. 4-((6-(Cyclo-
hexylmethoxy)-9H-purin-2-yl)amino)benzenesulfo-
namide (NU6102) is a potent and selective ATP-com-
petitive inhibitor of CDK2 in which the sulfonamide
moiety is positioned close to a pair of lysine residues.
Guided by the CDK2/NU6102 structure, we designed
6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-
9H-purin-2-amine (NU6300), which binds cova-
lently to CDK2 as shown by a co-complex crystal
structure. Acute incubation with NU6300 produced
a durable inhibition of Rb phosphorylation in SKUT-
1B cells, consistent with it acting as an irreversible
CDK2 inhibitor. NU6300 is the first covalent CDK2 in-
hibitor to be described, and illustrates the potential
of vinyl sulfones for the design of more potent and
selective compounds.
INTRODUCTION
Cyclin-dependent kinases (CDKs) play significant roles in regula-
tion of the eukaryotic cell cycle and in transcription (Lim and Kal-
dis, 2013; Malumbres and Barbacid, 2009). During G1 phase,
CDK2 bound to cyclin E mediates phosphorylation of the retino-
blastoma tumor suppressor protein (Rb), which results in activa-
tion of members of the E2F family of transcription factors,
thereby assisting entry into S phase (Morgan, 2007). Following
degradation of cyclin E during late G1, CDK2 pairs with cyclin
A to phosphorylate and inactivate E2F, resulting in S-phase pro-Chemistry & Biogression. Deregulation of the cell cycle is a characteristic of most
human tumors, occurring frequently through disruption of the Rb
signaling circuit. Aberrant control of CDK activity has been
directly linked to cancer development (Malumbres andBarbacid,
2009).
Chemical-genetic evidence has shown a difference in the
cellular response to the absence of CDK2 and to small-molecule
CDK2 inhibitors (Guha, 2012; Horiuchi et al., 2012; Malumbres
and Barbacid, 2009). These observations suggest that CDK2 in-
hibitors may be appropriate for treating a subset of tumors with
defined genetic characteristics. Strategies that exploit synthetic
lethalities have also highlighted a potential role for CDK2 inhibi-
tors. Combined administration of a phosphatidylinositol 3-kinase
inhibitor and a CDK2 inhibitor demonstrated induction of
apoptosis in malignant glioma xenografts (Cheng et al., 2012).
CDK2 inhibitors may also have clinical utility in subsets of can-
cers such as high-grade serous ovarian carcinomas, which har-
bor amplifications in the CCNE1 gene that encodes its partner
cyclin E (Etemadmoghadam et al., 2013).
The majority of protein kinase inhibitors in clinical trials are
reversible competitive inhibitors that bind to the enzyme’s ATP
binding site. Protein kinase activation is accompanied by signif-
icant structural rearrangement of the kinase fold, and this has
been exploited to identify compounds with increased selectivity
and potency (Dar and Shokat, 2011; Zhang et al., 2009). In this
context, irreversible inhibition may be extremely effective for
the subset of kinases that encode residues within the active
site that can be covalently modified and are not widely
conserved (Barf and Kaptein, 2012; Leproult et al., 2011).
Furthermore, covalent inhibitors can be useful tool compounds
in target validation studies to investigate the cellular effects of
selective protein kinase inhibition.
We present biochemical and structural studies that confirm 6-
(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine
(NU6300) as the first example of an irreversible inhibitor of CDK2.
We identify the site of covalent modification as Lys89, a residuelogy 22, 1159–1164, September 17, 2015 ª2015 The Authors 1159
Figure 1. Compound Structuresthat lies just outside the CDK2 ATP binding cleft and is not well
conserved across the protein kinase family. Our studies define
the inhibitor mode of action and show that selective irreversible
CDK2 inhibition can be achieved in cells.
RESULTS
Identification of NU6300, a Covalent ATP-Competitive
Inhibitor of CDK2
4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)benzenesulfo-
namide (NU6102, Figure 1) (Davies et al., 2002) is a low-nano-
molar inhibitor of CDK2 (Ki CDK2 = 6 nM), but has a modest
GI50 (8 mM) against human MCF-7 breast carcinoma cells. As
this unexpected lack of cellular activity may result in part
from the metabolic instability of the sulfonamide group (Shear
et al., 1986), a sulfone isostere was considered as a replace-
ment, resulting in the discovery of 6-(cyclohexylmethoxy)-N-
(4-(methylsulfonyl)phenyl)-9H-purin-2-amine (NU6155) (Hard-
castle et al., 2004; Figure 1).
NU6155 retained nanomolar inhibition of CDK2 and led, via a
novel synthetic approach, to a library of 2-(aminoethyl)sulfones
of general structure X (Griffin et al., 2006; Figure 1). The vinyl sul-
fone 6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-pu-
rin-2-amine (NU6300) was an intermediate in the synthetic pro-
cess and was recognized as a potential irreversible CDK2
inhibitor by acting as a Michael acceptor, as already demon-
strated for mechanism-based cysteine protease inhibitors (Vicik
et al., 2006). As expected, 6-(cyclohexylmethoxy)-N-(4-(ethylsul-
fonyl)phenyl)-9H-purin-2-amine (NU6310, Figure 1), in which an
ethyl replaces the vinyl group of NU6300, was a non-covalent
ATP-competitive CDK2 inhibitor (CDK2 median inhibitory con-
centration [IC50] = 0.16 mM).
NU6300 Binds Covalently to CDK2
To determine whether NU6300 binds covalently to CDK2, re-
combinant CDK2/cyclin A was incubated overnight with
NU6300 and then analyzed by electrospray ionization mass
spectrometry (ESI-MS) (Figure S1A). This analysis revealed
an increase in the mass by 414 Da compared with the control1160 Chemistry & Biology 22, 1159–1164, September 17, 2015 ª201CDK2 samples, supporting the formation of a covalent
adduct.
A similar experiment was also carried out using a surface plas-
mon resonance (SPR) biosensor. By exposing immobilized
CDK2/cyclin A to NU6300, the binding of NU6310 decreased.
This competitive effect indicates that NU6300 blocks the inhibi-
tor binding site. The effect was time dependent and relatively
slow, with less than 50% reduction of the apparent binding ca-
pacity in 20 hr (Figures S1B–S1D).
To determine the kinetics of the interactions of NU6310 and
NU6300 with immobilized CDK2/cyclin A, the sensor surface
was exposed to five different concentrations of each inhibitor
for different contact times (Figures 2A and 2B). On these rela-
tively short time scales (compared with the experiment above),
the interactions between CDK2 and either NU6300 or NU6310
appeared reversible, since the sensorgrams were well
described by a simple 1:1 model and the dissociation was
similar irrespective of the contact time. It enabled the estima-
tion of the kinetic constants (kon, koff, KD) for the formation of
the non-covalent complex. The values were 0.545 ± 0.072 3
105 M1 s1 (kon), and 0.0713 ± 0.0063 s
1 (koff), respectively,
yielding a KD of 1.31 ± 0.18 mM for NU6300, and 1.13 ±
0.10 3 105 M1 s1 (kon) and 0.0809 ± 0.0070 s
1 (koff), yielding
a KD of 0.716 ± 0.012 mM for the interaction of NU6310 with
CDK2. The formation of a covalent complex could not be de-
tected on the time scales of these experiments, and the injec-
tion times could not be extended further for practical reasons.
The inability to detect the formation of a covalent bond was not
attributable to inhibitor instability, as they showed unchanged
kinetic characteristics over several hours after preparation in
aqueous buffer.
To confirm the results of the ESI-MS and SPR analysis,
CDK2/cyclin A was incubated with either NU6300 or NU6310,
then the samples and appropriate controls were dialyzed. The
resulting CDK2/cyclin A activity was analyzed in an in vitro ki-
nase assay against a C-terminal fragment of the retinoblastoma
protein Rb. After an overnight incubation in the presence of
NU6300, CDK2 activity was not recovered after dialysis (Fig-
ure 2C). However, the non-covalent inhibitor NU6310 was
removed by this treatment, and the resulting CDK2 could phos-
phorylate Rb. The activity of NU6300 was also characterized in
an alternative kinase assay format (ADP-Glo;, Promega) in
which covalent inhibition of CDK2/cyclin A was allowed to pro-
ceed in a pre-incubation phase and was assessed in a subse-
quent activity assay, where enzyme and inhibitor were diluted
such that the inhibitor was present at 20-fold below its IC50
value. The samples and appropriate controls were incubated
for 0, 10, 30, 60, and 120 min, prior to addition of ATP and pep-
tide substrate (sequence HHASPRK, single-letter amino acid
code), to initiate the kinase reaction. The results of the study
indicate a time-dependent inhibition of CDK2/cyclin A by
NU6300, with the extent of inhibition increasing linearly with
time, consistent with irreversible inhibition occurring in the initial
rate regime (Figure 2D). The corresponding kinact for this pro-
cess is 5.0 3 103 M1 s1. Taken together, these results are
consistent with a model in which the two inhibitors have equiv-
alent micro-rate constants for their interaction with CDK2, but
in which upon extended exposure NU6300 covalently modifies
CDK2.5 The Authors
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Figure 2. NU6300 Is a Covalent Inhibitor of
CDK2
(A and B) SPR sensorgrams for the interaction
between immobilized CDK2 and NU6310 and
NU6300. (A) The effects of time on the interaction
were evaluated by comparing the dissociation
rates for the compounds injected at 10 mM for
different contact times (30, 60, 120, and 240 s).
Sensorgrams are aligned with respect to the start
of the dissociation.
(B) The determination of rate constants was based
on global analysis of a set of sensorgrams re-
corded for a concentration series (39, 156, 625,
2,500, and 10,000 nM) of the compounds. Theo-
retical curves of a fitted 1:1 Langmuir interaction
model (black) are overlaid on the experimental
traces.
(C) Phosphorylation of GST-Rb by CDK2/cyclin A.
The slower-migrating band is hyperphos-
phorylated GST-Rb (Phospho-Rb). Time points (in
minutes) are shown above.
(D) Time-dependent inhibition of CDK2/cyclin A.
Activity was measured using the ADP-Glo assay
format against a peptide of sequence HHASPRK.
Error bars indicate SD of the measurements.
See also Figure S1 and Table S1.Identification of CDK2 Residues Covalently Modified
by NU6300
Guided by the structure of the CDK2/cyclin A/NU6102 complex
(Davies et al., 2002), the nucleophilic residues that are suitably
positioned to react with the vinyl sulfone of NU6300 are Asp86,
Lys88, and Lys89. These residues were individually mutated to
an alanine, glutamate, or valine, respectively, and the resulting
mutant CDK2/cyclin A complexes were analyzed by ESI-MS
following overnight incubation with either NU6300 (exact mass
413.15) or DMSO (Figure S2 and Table S1). After treatment with
the inhibitor, the major CDK2D86A and CDK2K88E species were
modified by addition of 414 and 412 Da, respectively, whereas
the major species present in the CDK2K89V sample acquired no
additional mass.Chemistry & Biology 22, 1159–1164, SeThe bandshift experiment was re-
peated after incubating CDK2K88E/cyclin
A and CDK2K89V/cyclin A with NU6300,
NU6310, or DMSO followed by dialysis
to remove unbound inhibitor (Figure S2G).
The two mutants and wild-type CDK2
recovered their activity following treat-
ment with NU6310. CDK2K89V/cyclin A
recovered activity following incubation
with NU6300 and subsequent dialysis.
However, the CDK2K88E mutant and
wild-type CDK2 did not. These results
prove that Lys89 is the preferred site of
modification by NU6300.
To confirm this conclusion, NU6300
was co-crystallized with CDK2/cyclin A
and the structure was resolved to 2.4 A˚
resolution (Table S2 and Figure 3). As
has been previously observed withinthis inhibitor series, the purine ring makes a triplet of conserved
hydrogen bonds with the backbone amide and carbonyl groups
of Glu81 and the backbone carbonyl of Leu83 within the CDK2
hinge. The aniline moiety adopts a similar pose to that previ-
ously observed in the CDK2/NU6102 co-complex, packing
against CDK2 through a p-p interaction with the peptide back-
bone between Asn85 and Asp86, thus positioning one of the
sulfone oxygens to interact with the side chain of Asp86 (Davies
et al., 2002). As a result, the vinyl moiety can react with the
side-chain ε-amino group of Lys89 (Figure 3B). In this region,
the electron density map has continuous density between the
side-chain amino group of Lys89 and the inhibitor’s vinyl sul-
fone, indicating the formation of a covalent bond between
them (Figure 3C).ptember 17, 2015 ª2015 The Authors 1161
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Figure 3. Crystal Structure of NU6300 Bound
to CDK2/Cyclin A
(A) CDK2 and cyclin A are rendered in ribbon rep-
resentation and colored mint blue and lemon,
respectively. NU6300 is shown in ball-and-stick
representation, with carbon atoms in yellow.
(B) Schematic representation of the hydrogen
bonds made between backbone atoms of CDK2
residues Glu81, Leu83, and Asp86, located in the
hinge region, and NU6300 to illustrate the binding
mode. Hydrogen bonds are drawn as arrows.
(C) Electron density map at the CDK2 active site.
The 2F0-Fc map is contoured at 0.2 e
 A3. CDK2
and NU6300 carbon atoms are colored green and
yellow, respectively.
See also Figure S2 and Table S2.NU6300 Inhibits Rb Phosphorylation in Rb-Positive
SKUT-1B Cells
Our results demonstrate that NU6300 is a covalent inhibitor of
CDK2. Prior to determining its cellular activity, we carried out
a screen to assess its selectivity against a panel of 131 protein
kinases under conditions that would not distinguish between a
reversible or irreversible mode of action. This screen identified
13 kinases that exhibited less than 25% activity in the presence
of 1 mM NU6300 (Table S3A). These 13 kinases and 29 addi-
tional kinases, selected for their known sensitivity to other inhib-
itors within the purine series, were then tested in a modified
screening format in which the assay was repeated following a
4-hr pre-incubation (Table S3B). A comparison of the IC50
values revealed that in addition to CDK2, only Aurora A, Mst2,
and GCK (MAP4K3) showed a >50% additional loss of activity
after pre-incubation. This result suggests that they are also irre-
versibly inhibited by NU6300. An inspection of the Mst2 (PDB:
4LG4) structure revealed that it has a C-terminal helix that posi-
tions a lysine residue at a suitable distance and geometry for
covalent modification by a molecule of NU6300 bound within
the ATP binding site (Figure S3). The structure of Aurora A
(PDB: 2J4Z) does not suggest an immediate reactive group
for the vinyl sulfone moiety (the residues equivalent to CDK2
Lys88 and Lys89 are Tyr219 and Arg220). However, conforma-
tional flexibility around the active site may promote such an
interaction with a residue from another part of the structure
(Martin et al., 2012). Taken together, these results suggest
that NU6300 is not expected to have considerable off-target ac-
tivity in cells.
The cellular potency of NU6300 was examined by measuring
the inhibition of Rb phosphorylation following exposure of
SKUT-1B cells to the inhibitor for 1 hr. Pre-incubation with1162 Chemistry & Biology 22, 1159–1164, September 17, 2015 ª2015 The Authors50 mM NU6300 inhibited phosphorylation
of Rb at Thr821, a known CDK2 phos-
phorylation site, by 43%. After a 1-hr
drug washout in drug-free media, the inhi-
bition of Rb phosphorylation was 33% of
the untreated control, indicating that
more than 75% of the inhibitory activity
had been retained (Figure 4). This differ-
ence just reached statistical significance
(p = 0.04). In contrast, NU6102 at 50 mMinhibited phosphorylation of Thr821 on Rb by 85%, but within
1 hr of washout only 40% inhibition was observed, which repre-
sented a highly statistically significant change (p = 0.0003) and
indicated that just over half of the inhibitory activity had been
lost. These data are consistent with NU6300 having irreversible
activity against CDK2 in cells.
DISCUSSION
A number of CDK2-specific inhibitors with diverse pharmaco-
phores have been structurally characterized (Hardcastle
et al., 2002). Our results suggest that these molecules could
be modified by taking a similar approach to that described
herein, thus generating more structurally diverse irreversible
CDK2 inhibitors to explore the potential of CDK2 inhibition in
combination chemotherapies. While we have demonstrated
that NU6300, an irreversible inhibitor of CDK2, can reach and
modulate its target within cells, it remains to be established
whether this activity can enhance growth inhibition in a suitable
cell line model.
A recent report has also demonstrated that CDK7 can be
covalently modified following incubation with an inhibitor bound
at the ATP binding site (Kwiatkowski et al., 2014), suggesting that
this strategy may be applicable to the wider CDK family. For
example, CDK1 and CDK5 both encode a lysine residue equiva-
lent to CDK2 Lys89. Profiling NU6300 against a range of kinases
revealed limited off-target activity. We hypothesize that unex-
pected cross-reactivity arises from the warhead forming cova-
lent interactions with appropriately positioned amino acid side
chains that originate from distinct parts of the kinase fold, and
that this activity may be abrogated by judicious substitution on
the vinyl sulfone moiety.
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Figure 4. NU6300 Inhibits Rb Phosphoryla-
tion in Cells
(A) Rb phosphorylation in SKUT-1B cells after 1 hr
of incubation with NU6300 (50 mM) or NU6102
(50 mM) followed by washout, then harvested at the
indicated times. Representative of three different
experiments.
(B) Percentage of inhibition of phosphorylation of
Rb at Thr821 by NU6300 (50 mM) and NU6102
(50 mM) after washout of the inhibitors. Protein
expression levels of phospho-Rb (Thr821) were
normalized to the levels of total Rb in respective
samples using densitometry. Relative protein
expression levels are presented as percentage of
inhibition of phosphorylation of Rb (Thr821)
compared with the control cells for each time point.
Error bars represent the mean value and SD from
three independent experiments. Statistical analysis
was performed using the unpaired Student’s t test,
one-tailed.SIGNIFICANCE
Protein kinase inhibitors that bind covalently within the en-
zyme’s active site offer an attractive alternative route for
developing drugs against this clinically important protein
family. CDKs have significant roles in regulating both the
cell cycle and transcription in eukaryotic cells. They have
been the subject of intensive studies resulting in a number
of drugs entering clinical trials for cancer treatment. We
describe the first example of an irreversible inhibitor that tar-
gets CDK2 by grafting a reactive vinyl sulfone moiety onto a
potent reversible CDK2 inhibitor. The structure of the CDK2/
cyclin A/NU6300 complex reveals the inhibitor bindingmode
within the ATP binding site and confirms that the vinyl sul-
fone forms a covalent bond to the ε-amino group of Lys89.
Furthermore, this structure suggests how the reactive moi-
ety could be grafted onto other CDK2-selective pharmaco-
phores to develop inhibitors that specifically target CDK2.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Recombinant human CDK2, cyclin A2 (residues 174–432), Rb (residues 792–
928), and Saccharomyces cerevisiae CAK1 were expressed in EscherichiaChemistry & Biology 22, 1159–1164, Secoli cells and purified by a combination of affinity
and size-exclusion chromatography. See Supple-
mental Experimental Procedures for further
details.
Kinase Assays
CDK2/cyclin A kinase assays were carried out us-
ing a method modified from Brown et al. (1999) or
by using the ADP-Glo assay (Promega) essentially
as described by the manufacturers. A full descrip-
tion of the assay formats is provided in the Supple-
mental Experimental Procedures.
Interaction Analysis
The interaction experiments were performed using
SPR biosensor technology, with Biacore S51 andT100 instruments, CM5 biosensor chips, and standard reagents (GE Health-
care). Full details can be found in the Supplemental Experimental Procedures.
Crystallography
The CDK2/cyclin A/NU6300 complex was crystallized as described by Da-
vies et al. (2002). Data processing was carried out using programs of the
CCP4 suite (CCP4, 1994), run through the CCP4i2 GUI. The structure was
then solved by molecular replacement using Phaser (McCoy et al., 2007)
and a high-resolution structure of a recruitment peptide bound to CDK2/cy-
clin A (PDB: 2CCH) as a search model. Structures were refined using
REFMAC (Murshudov et al., 1997), interspersed with manual rebuilding in
Coot (Emsley et al., 2010), including TLS (translation/libration/screw) refine-
ment. Full details can be found in the Supplemental Experimental Proce-
dures. The statistics for the datasets and crystallographic refinement are
presented in Table S2.
Western Blotting
Western blot analysis was carried out as described previously (Thomas et al.,
2011) using rabbit anti-T821 phospho-Rb antibody (Invitrogen) or mouse anti-
human Rb antibody (BD Pharmingen) to detect phosphorylated and total
retinoblastoma protein, respectively. Sample preparation is described in Sup-
plemental Experimental Procedures.
ACCESSION NUMBERS
The coordinates and structure factors of CDK2/cyclin A/NU6300 have been
deposited in the PDB with accession code PDB: 5CYI.ptember 17, 2015 ª2015 The Authors 1163
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.07.018.
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